- Home
- GNS vs NRSN Comparison
GNS vs NRSN Comparison
Compare GNS & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNS | NRSN |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | Singapore | Israel |
| Employees | N/A | 15 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.1M | 28.4M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | GNS | NRSN |
|---|---|---|
| Price | $0.34 | $0.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 772.4K | 151.3K |
| Earning Date | 03-09-2026 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $220.56 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $0.68 |
| 52 Week High | $1.92 | $2.60 |
Technical Indicators
Market Signals| Indicator | GNS | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 37.06 | 40.45 |
| Support Level | $0.30 | $0.68 |
| Resistance Level | $0.48 | $1.30 |
| Average True Range (ATR) | 0.03 | 0.07 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 0.86 | 15.83 |
Price Performance
Historical ComparisonAbout GNS Genius Group Limited
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company's business consists of two reportable business segments: Education, which involves entrepreneur education, management consultancy, and business development tools; and Campus, consisting of resorts, retreats, and co-working cafes for entrepreneurs. It derives the majority of its revenue from the Education segment. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America. The company derives maximum revenue from Europe/Middle East/Africa.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.